Regeneron, Sanofi Announce Positive Results for Dupilumab for Infants, Children


The data presented shows that at 16 weeks, individuals who added the atopic dermatitis drug to low potency standard-of-care topical corticosteroids experienced 28% achieved clear or almost-clear skin.

Regeneron Pharmaceuticals, Inc, and Sanofi have announced detailed positive phase 3 results showing that adding dupilumab (Dupixent) to standard-of-care topical corticosteroids (TCS) can significantly improve skin clearance and reduce itch and overall disease severity in infants and children aged 6 months to 5 years with uncontrolled moderate-to-severe atopic dermatitis (AD).

The findings were presented in a late-breaking session at the 2021 Revolutionizing Atopic Dermatitis Conference.

About 85% to 90% of individuals with AD develop symptoms before aged 5 years that can often continue into adulthood, according to a statement from Regeneron.

Symptoms can include intense and persistent itch, as well as skin lesions covering the body, about (58% of individuals, on average, in this sample) and can results in skin cracking, crusting, darkening, dryness, oozing, or redness, as well as an increased risk of skin infections.

"These results show dupilumab can significantly improve the signs and overall severity of atopic dermatitis in children as young as 6 months. Safety is of paramount importance when treating children at such a young age,” Amy Paller, MD, chair of dermatology and professor of pediatrics at Northwestern University Feinberg School of Medicine, said in a statement.

“We are encouraged that these data show a safety profile consistent with what has been seen in other age groups,” she said. “We will continue to follow these patients for up to 5 years in an open-label trial."

The topline results were from a placebo-controlled, randomized pivotal trial, which met all primary and secondary endpoints, which were announced in August 2021.

The data presented showed that at 16 weeks, 28% of individuals who added dupilumab to low-potency TCS achieved clear or almost-clear skin compared with 4% with the placebo, which was the primary endpoint.

Additionally, 70% of individuals had average improvement from the baseline in disease severity compared with 20% improvement with the placebo, which was a key secondary endpoint.

About 53% of individuals achieved 75% or greater improvement from the baseline compared with 11% with the placebo, which was the co-primary endpoint outside the United States.

About 49% of individuals averaged improvement from the baseline in itching compared with 2% improvement with the placebo.

The safety profile observed was consistent with the known safety profile of dupilumab in individuals aged 6 years or older with moderate-to-severe atopic dermatitis. Overall rates of adverse events (AEs) were 64% for dupilumab and 74% for the placebo.

The most common AEs were nasopharyngitis (8% for dupilumab and 9% for the placebo), upper respiratory tract infections (6% and 8%, respectively), conjunctivitis (5% and 0%, respectively), and herpes viral infection (6% and 5%, respectively).

These results will form the basis of global regulatory submissions for this age group, beginning in the United States in 2021 and the European Union in the first half of 2022.

Long-term data from the phase 3 trial for individuals aged 6 to 11 years with moderate-to-severe atopic dermatitis will also be presented. The efficacy and safety results at 1 year were consistent with the known profile of dupilumab for atopic dermatitis.

The data from these trials adds to the extensive LIBERTY AD clinical program, involving 3500 infants, children, adolescents, and adults to date.


Positive phase 3 Dupixent (dupilumab) data in children 6 months to 5 years with moderate-to-severe atopic dermatitis featured in RAD 2021 late-breaking session. Regeneron. News release. December 13, 2021. Accessed on December 13, 2021.

Related Videos
Laboratory test tubes and solution with stethoscope background | Image Credit: Shutter2U -
Image credit: Andrea Izzotti
Inflation Reduction Act is shown using the text and the US flag - Image credit: Andrii |
Pharmacy Interior | Image Credit: Tyler Olson -
Male pharmacist selling medications at drugstore to a senior woman customer | Image Credit: Zamrznuti tonovi -
Pharmacist assists senior woman in buying medicine in pharmacy - Image credit: Drazen |
Pharmacy, medicine and senior woman consulting pharmacist on prescription. Healthcare, shopping and elderly female in consultation with medical worker for medication box, pills or product in store - Image credit: C Daniels/ |
Image credit: fidaolga -
Pharmacists checking inventory at hospital pharmacy- Image credit: Jacob Lund |
Young male pharmacist giving prescription medications to senior female customer in a pharmacy | Image Credit: Zamrznuti tonovi -
© 2023 MJH Life Sciences

All rights reserved.